PFL 002
Alternative Names: PFL-002; PFL-002/VERT-002; VERT-002Latest Information Update: 11 Jun 2024
At a glance
- Originator Vertical Bio
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 05 Jun 2024 Pierre Fabre Laboratories files an IND application with the US FDA in USA for non-small cell lung cancer
- 12 Sep 2023 Vertical Bio has been acquired by Pierre Fabre Laboratories
- 12 Sep 2023 Preclinical trials in Non-small cell lung cancer in Switzerland (Parenteral), prior to September 2023